Good Prolaris Score, Seeking Advice

____________________________________________________________________

Previous Threads;

http://www.healingwell.com/community/default.aspx?f=35&m=3418633

http://www.healingwell.com/community/default.aspx?f=35&m=3423082

Age: 58 (wife/small children)
Excellent health (full court basketball, 1-2 times/wk.)
PSA: 4.6 (5/2014), 17 (5/2015)
MRI (5/22/15) revealed 2 lesions that were "clinically significant."
Consultation on 6/9/15 with a well-regarded urologic oncologist at NYU Langone Medical Center in NYC
Biopsy with same urologic oncologist on 6/12/15

Biopsy Results:

From Standard 12 Core Biopsy;

1. Left lateral base: adenocarcinoma, G 3+3=6 involving one core (4mm; 40%)

2. Left lateral mid: Prostatic tissue with small focus of atypical glands

4. Left medial base: adenocarcinoma, G 3+3=6 involving one core (2mm; 15%)

9. Right medial apex: adenocarcinoma, G 3+3=6 involving one core (1.5 mm; 10%)

10. Right lateral base: adenocarcinoma, G 3+3=6 involving one core (3mm; 25%)

All other cores: Benign Prostate Tissue

From MRI-guided Biopsy:

13. Posterolateral Mid/Apex PZ, Right: adenocarcinoma, G 3+3=6 involving four of five cores (4mm, 40%; 2mm, 15%; 3mm, 20%; 2mm, 20%)

14. Posterolateral Mid PZ, Left: adenocarcinoma, G 3+3=6 involving three out of five cores (3mm, 40%; 3mm, 30%; 1mm, 10%)

15. Anteromedial Apex PZ, Right: Prostatic tissue with small focus of atypical glands

_____________________________________________________________________


Went for additional opinions from another surgeon and an RO at Memorial Sloan Kettering in NYC.

---Had another MRI done which revealed similar results as the first

---Had another PSA test done which came in at 5, considerably lower than the previous 17

---Had a Prolaris test done on my biopsy tissue which came in at -1.9 which is "Less Aggressive" and borderline "Considerably Less Aggressive."

"Interpretation: The patient has a 10-year mortality risk of 2% [from prostate cancer] if managed conservatively."

---Clinical T Stage: T1c

---% Positive Cores: 87% (7/8)

---Gleason Score: 3+3=6


Seeking advice on next course(s) of action.

Thanks in advance.
Earl

Hopefully, others who comprehend Prolaris better than I do can respond.

In my case I had fewer cores with indications, but one was a GL 7.

Also had Prolaris with a similar finding to yours. In the end I wasn't sure how much credence to give to the Prolaris and I elected to have treatment.
Age 61, Fit
-DX Jan 2015
-PSA (Finasteride reduced) 2/15 - 3.46, 9/14 - 3.38, 8/14 - 2.5, 2/14 - 2.1, 9/13 - 1.7, 12/12 - 1.4

HDR Brachytherapy at UCLA 4/30 and 5/7

-2 cores positive - 30-40%
-Gleason 7 (3+4)
I also give little credence to Prolaris scores. It's just a company that put together some DNA markers for prostate cancer. Whether these markers cover all of the many mutations that give rise to prostate cancer in its many varieties remains to be determined by solid scientific evidence.

On the other hand, your numbers (Gleason scores and PSA) look extremely favorable for a good outcome. The MSK doctors, much more knowledgeable of course, came to the same conclusion.

Whether you want treatment or enter an Active Surveillance program is up to you. I know what I would choose, but that hardly matters.
DOB 1940
Dec 2012: GP discovered a nodule and hardened prostate; confirmed by urologist
PSA: 11.9 ng/ml
Biopsy (3/1/2013): Gleason 4+5 (enlarged; 45 ml)
Stage: T2c
Transferred to RO
Casodex for one month; then Lupron 5/2013 through 12/2014 (18 months total)
Jul-Sep 2013: SBRT (CyberKnife; 3 x 6.5 Gy) followed by IMRT (25 x 1.8 Gy)
Lowest PSA thereafter: 0.1 (3/20/2015)
9/18/2015: PSA = 1.4 ng/ml
When I had a favorable result on my OncotypeDX test, my oncologist was not about to lessen my future testing. He said that such tests were useful in suggesting intervention if the results were pessimistic, but favorable results would not change the surveillance.

You would not be eligible for the AS program at Johns Hopkins due to your cancer being bilateral. That criterion was added by Dr. Epstein in 2014, who determined a higher risk if both sides were involved.

Just another opinion and facet of information for you to process. But, with only Gleason 6 found, you have very favorable prospects for outliving PCa.
DOB: May 1944
December 2010: PSA 3.4 biopsy negative, HGPIN
March 2012: PSA 4.4 biopsy abnormal cells, HGPIN
July 2012: Biopsy <5% 1 of 14 cores, 3+3; T1c
Enrolled in AS program at Johns Hopkins
September 2013 PSA 3.7 biopsy: < 5% 3 of 14 cores, 3+3
OncotypeDX: 86 percent chance of PCa remaining indolent
Sept 2014: Biopsy using 3T MRI fusion image: negative
July 2015: all good, no biopsy this year
With all that extra testing (mpMRI targeted biopsy, Prolaris) I think you should feel reasonably confident that your "low risk" diagnosis is accurate - at least for now. I assume that MSKCC and/or NYU told you that active surveillance is a reasonable option for you. They probably also told you that all radical therapies are reasonable as well. Is that where you are right now?

If so, it's a good time for self-assessment. Are you the type of person who can live with active surveillance, or would the anxiety kill you? What is the baggage you carry in your mind about cancer - are those thoughts and feelings reasonable? Are there any you might be better off letting go of? Is there pressure from others - real or imagined? Can you live without a pathology report and with detectable PSAs? What are the side effects that really frighten you - incontinence, impotence, size loss, catheterization, urinary frequency, rectal bleeding, etc.? I worked with a psychotherapist for several months exploring my attitudes about such things in perhaps a more guided and structured manner than I would be able to do on my own. I also learned some great Mindfulness techniques to keep me present-oriented and not worrying about imagined future outcomes. It helped me with my decision and also in many other areas of my life. You might also benefit from a PC Support Group.

Armed with a clear knowledge of yourself, I think it facilitates evaluating alternatives. A lot of options are "right," but it has to be "right for you."

- Allen
Thank you all very much for responding.

Works Out and Sr Sailor;

Actually, the doctors at both NYU and MSKCC do seem to give a fair amount of credence to the Prolaris scores. Certainly, it is one data point among a number of parameters, but yes, my impression was that this is relatively new technology and it is increasingly being considered in the overall decision-making process for an increasing number of patients.

ASAdvocate and Tall Allen;

Yes, I have discussed active surveillance as well as all radical PCa therapies. And Allen, you raise a number of very interesting questions regarding one's psychological makeup and the "right" therapy for each individual. And I think when I consider my present overall situation, I'm leaning towards AS.

I guess my biggest question(s) at this point are what/how would/could change my "low risk" diagnosis? How accurate is the mpMRI targeted biopsy? Can G6's change into something more aggressive? And what is typically involved with AS?

Any additional information and/or help would be most appreciated.

Thanks again, in advance.
I too have to ask the same question by Earl96.

Can the existing tumor cancer evolve to a higher G-Score?
Can a new tumor come back with a higher G-score?
Does the Prolaris DNA gene score change for various tumors, or, is the cancer DNA gene makeup constant in the prostate?

Anyone with some research thoughts on the matter . . . .

Earl96, you asked a couple questions at the end of your last post which I can address.

 

What could change your status from “low risk” is the future growth of new cancer cells with Gleason pattern 5, or a lot of Gleason pattern 4 cells.  That could happen, but you already have consistently verified “low risk” PC and that definitely tends to be slow moving…so the “active” part of AS is meant to keep monitoring your case—more closely at first, and probably with less frequency as time successfully goes by—so that you would move into successful treatment if and when such changes occur.

 

3+3 doesn’t metastasize or grow into something more aggressive, but as I said you might some day in the future grow a more aggressive version of PC.  Of course, you might also get hit by a Mack Truck tomorrow, too, if you get what I mean…

 

mpMRIs are accurate at identifying aggressive PC, and they are not sensitive to non-aggressive PC patterns.  mpMRIs are now commonly used in conjunction with AS programs for ongoing monitoring, especially as they are becoming more widely available.

 

Lastly, you asked:  What’s typically involved with AS?….hmmm, where to start…?

 

There has been some good threads about AS written here at HW.  Here’s something at JackH recently posted which I’ll simply copy/paste (that thread topic was a little different, but good info nonetheless):

 

ACTIVE SURVEILLANCE FUNDAMENTAL #1: AS is only for well-selected men diagnosed with PC. This is why “Step #1” for newly diagnosed men is to understand your risk category (see “Newly diagnosed…” thread). AS is not for men with high risk cases. Intermediate risk…maybe. This category has been split into two groups: 4+3 unfavorable intermediate risk cases, and 3+4 favorable intermediate risk cases, with other case characteristics also weighing-in. A number of AS programs have been including favorable intermediate risk cases. Low risk cases are the obvious candidates, and Johns Hopkins has had strict guidelines (although they have relaxed their AS criteria a couple years ago).

AS FUNDAMENTAL #2: Despite the limitation of being "well-selected" in #1, above, a huge percentage of newly diagnosed men are suitable for Active Surveillance as a first-line management strategy. Some AS programs are more restrictive than others, and there is currently no universally accepted formal protocol for AS entry, monitoring, or exit. Clinicians individually tailor a program of care to each individual case but based on common foundations. Using contemporary data of newly diagnosed cases in the US, somewhere between 40% and 67% of new PC cases are likely eligible for Active Surveillance, based on more and less restrictive program criteria.

AS FUNDAMENTAL #3: Some men who originally qualify for AS end up moving onward at a later date to a deferred treatment if signs indicate degradation in case characteristics. These men with deferred treatment are also “AS success stories!” (Please study and understand this PC Infolink article if you are confused by that statement: prostatecancerinfolink.net/2010/10/19/understanding-your-clinicians-mindset-about-active-surveillance/) The program worked for them, too, by showing them if and when treatment was appropriate. Complementary research has demonstrated that men on AS who move to deferred treatments have essentially the same outcome as those who sought immediate treatment. 

AS FUNDAMENTAL #4: Ongoing monitoring is important to the continued success of AS programs and men enrolled in AS programs. Annual PSA blood tests are the norm. In the past, on-going AS cases have follow-up biopsies (after the 2nd, confirmatory biopsy) on an every 18-24 month basis (typically), depending on the program. In the current decade, mp-MRIs have been found to be superior to the old standard ultrasonic-guided needle biopsy, and most AS programs now at least intersperse mp-MRIs with needle biopsies.